28159 Avenue Stanford, Suite 220 Valencia, CA 91355
T 833.462.8482 W avitamedical.com

2024 CORPORATE RESPONSIBILITY REPORT

Table of Contents

About this Report

This report details the progress and results of activities related to sustainability and corporate responsibility at AVITA Medical during the 2023 fiscal year, which ended December 31, 2023, unless otherwise noted. The content and metrics included in this report are guided by the Sustainability Accounting Standards Board (SASB) Standards for both Biotechnology & Pharmaceuticals and Medical Equipment & Supplies. Additionally, in producing this report, we relied on the results of our Environmental, Social, and Governance (ESG) materiality assessment completed in 2023. This report also includes explanations of our practices, policies, and programs, which may include more recent information.

Please send any comments or questions about this report to investors@AVITAMedical.com.

Forward Looking Statements

This report may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as "anticipate," "expect," "intend," "could," "may," "will," "believe," "estimate," "look forward," "forecast," "goal," "target," "project," "continue," "outlook," "guidance," "future," and similar words or expressions, and the use of future dates. Forward-looking statements in this report include but are not limited to statements relating to our current or future initiatives, strategies, and plans. These statements are made as of the date of this report, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the "Risk Factors" section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties.

A Message from Our CEO

On behalf of AVITA Medical, I am proud to share our inaugural Corporate Responsibility Report. This report illustrates how our mission reflects our values as we grow responsibly, sustainably, and ethically. It underscores our commitment to initiatives that not only align with our core values but also advance our mission to positively impact our customers and their patients, our employees, and our shareholders.

Over the past 2 years, we have executed our growth strategy and identified significant opportunities for continued expansion. On June 7th, 2023, we announced FDA approval of our RECELL® System for treating full-thickness skin defects, marking a pivotal milestone. This expanded indication allows us to pursue a multitude of applications across various medical specialties, including plastic, trauma, and general surgery.

On May 30th, 2024, we achieved another major milestone with FDA approval of RECELL GO, the next generation of our RECELL System. Developed through extensive research and innovation, RECELL GO reduces the training burden on medical staff, improves workflow efficiency in the operating room, and controls the RECELL Enzyme™ incubation time to ensure optimal cell yield and viability. By streamlining processes and enhancing operational efficiency, healthcare providers can treat more patients, further extending the proven benefits of our RECELL technology. We are especially proud that the first patient was successfully treated using RECELL GO just two days after FDA approval.

While RECELL remains the cornerstone of our portfolio, our vision is to evolve into a global, broad-based, wound care company. By building a portfolio that addresses the full continuum of clinical needs across burn, surgical, traumatic, and chronic wound care, we will improve accessibility and reach more patients. To achieve this goal, we have been actively exploring wound bed preparation, wound dressings, and dermal replacement products to complement RECELL. To that end, earlier this year, we added PermeaDerm®, a biosynthetic wound matrix, and we are currently developing an AVITA Medical-branded collagen-based dermal matrix with Regenity™ Biosciences. Both can be used alongside RECELL to treat burns and other wounds. Collectively, these products align with our vision of becoming a global leader in wound care.

As we continue to evolve, we will update our progress in future reports. I want to express my sincere gratitude to the entire AVITA Medical team for their passion and dedication since I joined as CEO in September 2022. We are making meaningful progress, and our current momentum has us well-positioned for continued growth.

Sincerely,

Jim Corbett
Chief Executive Officer

Our Company

Overview

AVITA Medical is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with first-in-class devices. Our portfolio of products addresses unmet medical needs in burn injuries, full-thickness skin defects, and skin repigmentation. We are headquartered in Valencia, CA, with manufacturing and shipping facilities in Ventura, CA, and an Innovation Hub in Irvine, CA.

Our Mission

At AVITA Medical, patients are at the core of everything we do. Our focus on regenerative medicine produces innovative approaches to wound care and healing skin, enabling transformative medical outcomes and setting new standards of care.

Our Vision

We envision AVITA Medical as a global provider of regenerative medicine solutions in wound care management that enhance patient care and recovery. We are committed to offering comprehensive treatment options to address the full spectrum of clinical needs, with the aim of improving accessibility and reaching more patients.

Our Core Values

We embrace the power of diversity to foster solutions, innovations, and advancements that positively impact the lives of patients and reflect our commitment to our employees, patients, and our shareholders. Our core values emphasize knowledgeable, patient-centered collaboration to provide physicians with safe, effective, and innovative medical devices and therapies. We operate under these shared values.

OUR VALUES

We believe that patients are at the heart of everything we do.

We believe that our employees are the lifeblood of AVITA Medical.

We believe that passion is key to making a difference at AVITA Medical.

We believe that quality impacts everything we do.

We believe that integrity is essential to our success.

AT A GLANCE*

- 200+ full-time employees
- Expanding U.S. Reach: Serving over 130 burn centers and 150+ trauma centers, with continued growth to support our broad indication in the full-thickness skin defect market
- RECELL System:
  - Conducted 13 randomized controlled clinical trials
  - More than 400 publications and presentations
  - Over 15,000 patients treated with RECELL since it received FDA approval

**As of June 30, 2024*

Our Products

Portfolio

Today, our portfolio of products is made up of two categories: RECELL® System devices and co-branded wound care products. At the forefront of our portfolio is RECELL approved by the U.S. Food and Drug Administration (FDA) for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. Within our co-branded portfolio of wound care products, we also hold the exclusive rights to market, sell, and distribute PermeaDerm® a biosynthetic wound matrix in the U.S.

In 2023, we launched efforts to build a portfolio of co-branded products and to expand internationally.

RECELL Technology

Our FDA-approved RECELL technology treats patients with thermal burn wounds and full thickness skin defects and is also used for re-pigmentation of stable depigmented vitiligo lesions.

RECELL harnesses the regenerative properties of a patient's own skin to create an autologous skin cell suspension, Spray-On Skin™ cells, delivering a transformative solution at the point-of-care. Designed for donor sparing, significantly less donor skin is required with similar healing outcomes versus conventional autografting. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes.

The donor-sparing nature of RECELL means, on average, treatment requires:

- 97.5% less donor skin for deep, partial-thickness burns;[1]
- 32% less donor skin for full thickness burns when used in combination with autograft;[2] and
- 27% less donor skin for full thickness skin defects when used in combination with autograft.[3]

These clinical benefits can in turn lead to cost savings.[4] Reduced donor skin requirements can result in fewer surgical procedures for definitive closure, decreased length of stay, and
reduced resource use, translating to potential cost savings[4-7], including:

- Up to 50% reduction in definitive closure procedures;[4]
- Up to 47% reduction in the length of stay for burns less than 50% of the total body surface area;[4] and
- Up to 39% total cost savings.[4]

RECELL is the only device of its kind marketed in the U.S. and approved by the FDA via a pre-market approval (PMA).

International

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe, and has PMDA approval in Japan.

Further, we have entered exclusive agreements with international distributors to market, sell, distribute RECELL in Austria, Belgium, Finland, Germany, Japan, Luxembourg, the Netherlands, Norway, Sweden, and Switzerland.

PermeaDerm

This January, we became the exclusive U.S. distributor of PermeaDerm by Stedical Medical. PermeaDerm is a porous, transparent, and flexible dressing that is cleared by the FDA for use in treating a wide range of wound types until healing is achieved. PermeaDerm's high level of permeability and flexibility allows clinicians to customize the porosity to meet the specific needs of the wound. This adjustability facilitates wound healing and can be used alongside the treatment of many of our burn and full-thickness cases to further aid the healing process.

Commitment to Patient Care

By addressing diverse clinical needs, we aim to improve accessibility and broaden our impact, ensuring comprehensive treatment options for patients.

Label Expansion

At AVITA Medical, patients are at the heart of what we do. From continuously innovating our products to expanding our product portfolio and comprehensive patient access program, we strive to transform patient lives.

In 2023, we achieved a significant milestone as we received FDA approval to use RECELL for the treatment of full-thickness skin defects. With this expanded indication, over 400,000 procedures are now eligible to be treated with RECELL. This expansion significantly broadens our reach to patients with many different applications and expands our customer base well beyond burn centers into trauma centers and other inpatient settings. Over 3,000 patients were treated with over 7,000 RECELL devices in calendar year 2023.

Next-Generation Device

At the end of May 2024, we received FDA approval of our PMA supplement for RECELL GO™, our next-generation device approved for the treatment of thermal burn wounds and full-thickness defects. RECELL GO introduces enhanced features that streamline the preparation of Spray-On Skin Cells by significantly reducing the training burden on medical staff, improving workflow efficiency in the operating room, and controlling the RECELL Enzyme™ incubation time to ensure optimal cell yield and viability.

We believe these advancements will empower clinicians to expand treatment capabilities, treat a greater number of patients, and more broadly experience the proven benefits of RECELL technology.

Burn Center Adoption

In 2023, we saw an increase in devices sold and patients treated as a result of increased adoption in burn centers.

Access Program

We have also developed a comprehensive patient access program to facilitate easier access to RECELL for both patients and their healthcare providers.

Clinical Trials

We are committed to ensuring the safety, health, and well-being of clinical trial participants and continuously monitor all aspects to minimize risks. We have established documented procedures to ensure that company-initiated clinical trials are conducted in compliance with The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Good Clinical Practice (GCP), and local regulatory and health authority requirements. In the U.S., the FDA also closely monitors the progress of each of the phases of clinical testing and may, at its discretion, re-evaluate, alter, suspend, or terminate the clinical trial based upon the data which have been accumulated to that point and the FDA's assessment of the risk/benefit ratio to the intended patient population.

In 2023, we had no inspections related to clinical trial management and pharmacovigilance that resulted in either entity voluntary remediation or regulatory or administrative actions taken against the entity. In addition, we had no monetary losses from legal proceedings arising from any clinical trial.

In 2023, we initiated the TONE Study to further evaluate repigmentation of stable depigmented vitiligo lesions with RECELL and to measure the improvement in the quality of patients' lives following treatment. In early 2024, the study was fully enrolled with 12-month patient follow-ups anticipated in the first quarter of 2025. In addition to this quality-of-life study, we have also initiated a health economics study to capture the longitudinal healthcare costs of vitiligo patients to help increase access to the treatment for patients.

Our Passion

Burn Camps

In the U.S., there are approximately 40 camps that host around 2,500 survivors of burn injuries annually. These camps are dedicated to young burn injury survivors, providing a safe and fun environment to encourage healing, personal growth and development, and friendships. The camps are all operated by non-profits and staffed by well-trained and passionate volunteers comprised of adult burn survivors, firefighters, burn care professionals, nurses, mental health specialists, and trained recreational leaders.

Since 2019, we have supported these camps, representing a cumulative attendance of over 7,500 campers. Each year, we offer resources to meet the particular needs of each camper. In 2023, we supported 38 camps with 1,720 campers. In addition to our financial support, our employees routinely volunteer at these burn camps throughout the year.

Grants and Donations

We have recently established a Grants & Donations Committee for evaluating multiple requests for charitable giving to organizations aligned with our values. In 2023, we donated over $140,000 to these organizations.

Our Employees

Employee Retention & Engagement

Our mission to transform patient lives relies heavily on our talented employees. We are committed to hiring, developing, and retaining highly qualified and motivated people, while providing each employee with an opportunity to make a difference. We provide our full-time employees a competitive benefits package that includes an Employee Assistance Program (EAP) to provide support for personal and/or work-related issues.

To support retention, we provide internal and external training and professional development programs that encourage our employees to grow and develop. We believe the success of our company is directly tied to the growth and fulfillment of our employees. Employee feedback is routinely solicited and engaged through monthly town hall meetings, micro-pulse surveys, and more comprehensive employee engagement surveys.

AVITA ACADEMY

STAMP FOR SENIOR LEADERSHIP

Specialized program designed to identify, nurture, and advance high-potential employees into key leadership roles

LEADAIR FOR ADVANCED LEADERSHIP

Advanced leadership program that develops strategic thinking and complex problem-solving skills

PASSPORT TO SUCCESS FOR NEW LEADERS

Focused development program offering structured content bundles to support the development of essential skills, fostering professional growth and enhancing contributions for those in new leadership roles.

TICKET TO GROWTH FOR INDIVIDUAL CONTRIBUTORS

Self-paced program created to span all organizational and soft skill functions, providing employees with continuous learning opportunities for career development and personal growth

Q1 2024 EMPLOYEE SURVEY RESULTS

- 94% of respondents feel a great sense of accomplishment
- 96% of respondents value their contributions to the overall operations

(110 responses)

Accountability

Throughout our company, we share a common vocabulary about our accountability to each other, patients, customers, and shareholders based on the Oz Principles. From a book of the same name, the Oz Principles seek to drive company results by establishing both individual and organizational accountability. These principles, "See It," "Own It," "Solve It," and "Do It," encourage us to identify issues or problems, take accountability for them, engineer solutions, and execute.

Health and Safety

We take the health and safety of every employee very seriously. In addition to the safety training described in the Quality System section, in 2023, we implemented a modern learning system with expanded modules for training on safety issues from the warehouse floor to the office desk to the representatives working out in the field.

In 2023, we had zero health and safety incidents, and only one worker's compensation claim.

Workplace Diversity

We understand that a diverse and inclusive workforce benefits us, patients, and our shareholders. We have robust policies prohibiting discriminatory practices in hiring or in the workplace. We engage recruiters who focus on sourcing talent from a diverse pool. Our diversity efforts are reflected in the composition of our workforce, which stands as a leader in the communities of each of our three locations.

We are also strongly diverse in the gender of our workforce. Across the entire organization, 48% of our employees identify as female and 52% identify as male. For director-level and below, there is a 50:50 split. In all positions outside of the C-suite, females on average earn more than their male counterparts.

DIVERSITY METRICS



Our Operations

Efficiency and Environmental Impact

We have taken concrete steps to reduce our impact on the environment. In 2023, we began leasing an Innovation Hub in a state-of-the-art, Irvine-based business park with Leadership in Energy and Environmental Design (LEED) certified buildings, electric vehicle charging stations, and other conservation-minded features. In addition to the efficient features of the building, this location significantly reduces the drive time for our employees located in Orange County and surrounding areas, making a small but real impact on greenhouse gas emissions.

Also in 2023, we started renovation plans for our Ventura-based manufacturing facility, which included thoughtfully selected features to increase efficiency and reduce energy consumption. These features include motion sensors and LED lighting, as well as removing inefficient fans and gas heaters in warehouse space, transitioning to a climate-controlled enclosed area for increased energy efficiency, and installing energy efficient heat pumps instead of traditional HVAC. We are pleased that the renovation was completed on time this July.

In November 2023, we completely eliminated cold chain packaging for the shipment of our RECELL devices, resulting in 137% weight reduction per unit shipped. This change results in packing efficiency and reduces shipping fuel use on a per-unit basis.

Our RECELL product is entirely used and disposed of in the operating theater by our customers. In the event a product is returned due to expiration, it is relabeled and used by the sales team for training and demonstration purposes. Any product that is returned for other reasons is broken down into its component parts (plastic, batteries, and printed circuit boards), each of which are recycled at an appropriate facility. In 2023, AVITA received approximately 0.071 metric tons of our product for either relabeling as a demonstration unit or recycling.

Product Design and Lifecycle Management

We are passionate about product design and lifecycle management for our products. In addition to having a 100% on-time shipping rate in 2023, every device component with an associated Material Safety Data Sheet (MSDS) has the MSDS stored on site. Each component of our device is identifiable by a lot number that is tracked throughout our production process. This information is maintained in a database to show the component pieces in every lot of finished products. Finished lot recipients (customers) are also tracked.

We are not aware of any attempt to counterfeit our products. Due to the highly specialized sales process and the legal and regulatory barriers to attempting to create a counterfeit product, risk of product counterfeiting is virtually zero.

Employees who interact with these components are trained to read and understand the MSDS prior to working with the device component. For any component that requires specialized safety equipment, we provide that equipment. Our workplace injury rate is less than 1%.

Our RECELL device is routinely recognized in double-blind studies as being a best-in-class product by the healthcare providers who use it to treat their patients. In addition to this general recognition, in September 2023, **RECELL** became a two-time winner of the ***Best Product Award*** at the Annual American Association for the Surgery of Trauma Conference.

Quality System

We know that healthcare providers are relying on the consistent high quality of our products to ensure the best patient outcomes. Our Quality Management System (QMS) is designed to comply with many international standards and foreign and domestic laws and regulations, including:

- EN ISO 13485:2016(E) Quality Systems: Medical Devices- Quality Management Systems- Requirements for Regulatory Purposes
- 21 CFR, Part 820, Quality System Regulation
- 21 CPR, Part 803, Medical Device Reporting
- 21 CFR, Part 806, Reports of Corrections and Removals
- Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (Medical Device Directive or MDD) as amended
- MDR 2017/745 Regulation (EU) 2017745 of the European Parliament
- Australian TGA Therapeutic Goods (Medical Devices)

Supply Chain Management

Our facilities are subject to routine inspection or audit by the FDA, EU Notified Bodies, and the Australian Therapeutic Goods Administration. All of our critical suppliers must be FDA registered or certified to the appropriate ISO standards. Additionally, in 2023, we began inviting critical suppliers to acknowledge our Supplier Code of Conduct. As of December 31, 2023, 60% of our critical suppliers had acknowledged our Code, or in the alternative, confirmed that they operate under a similar internal code.

Additionally, we operate an ongoing enterprise risk management evaluation that includes assessing the criticality of components used in our devices. Further, we aim to source at least two suppliers for every critical component or material.

Safety Track Record

We have no products listed in public safety or adverse event databases, no associated fatalities, no issued recalls, and no enforcement actions related to good manufacturing practices ("GMP").

Our Integrity

Governance

Our Board of Directors is comprised of six industry veterans with almost 200 years of collective experience in healthcare, technology, and life sciences. This wealth of experience empowers them to provide meaningful oversight and to support our strategic vision. Our Board's commitment to diversity is demonstrated by its composition, comprised of one-third women non-executive directors and an even split between U.S. and Australian directors (in light of the Company's dual-listing in both the U.S. and Australia).

Our Board operates under Corporate Governance Guidelines (https://ir.avitamedical.com/static-files/9ab22457-d90a-41e4-847b-610f9b27cdce) to ensure it meets its oversight obligations. These guidelines cover 16 core Board responsibilities:

- Role and function of the Board
- Responsibilities of directors
- Board, Committee, and annual shareholder meetings
- Board leadership structure
- Communication with third parties
- Confidentiality obligations
- Notice upon change of employment
- Composition and selection of the Board
- Appropriate service on other boards
- Operation of the Board
- Conflict of interest rules
- The Board's access to management and independent advisors
- Director training and education
- Director compensation
- Evaluation of executive management
- Management succession

Compliance

We strive to operate ethically and legally in everything that we do. As a demonstration of our commitment to the highest moral and ethical standards, we have adopted the AdvaMed Code of Ethics (https://www.advamed.org/member-center/resource-library/advamed-code-of-ethics/) as well as our own Code of Business Conduct and Ethics, with certified trainings administered annually. In 2024, we will roll out a comprehensive compliance program incorporating all of our existing polices, practices, and work instructions in a single guidebook. Certain compliance policies that govern our behavior include:

- Insider Trading and Securities Dealing Policy
- Disclosure and Communication Policy
- Whistleblower Policy
- Policy on Interactions with Healthcare Professionals
- Policy on Handling Reports of Compliance Violations
- Work Instruction (WI) 4.2.1 Handling Personal Data
- WI 4.2.2 MLR Review
- WI 4.2.4 External Generated Material
- WI 4.2.5 Social Media Policy

- WI 5.4.1 Reporting and Handling of Compliance Violations
- WI 5.5.1 California Compliance
- WI 5.5.3 National Physician Payment Transparency Program
- WI 7.2.4 Education Grants and Charitable Donations
- WI 7.2.5 Responding to Unsolicited Requests for Off-Label Information
- WI 7.2.7 Policy of Interactions with Healthcare Professionals
- WI 7.2.5 Responding to Unsolicited Requests for Off-label Information
- WI 7.2.6 Good Reprint Practices for the Distribution of Scientific and Medical Information

In 2023, the Compliance team continued to foster a culture of compliance when it, for example:

- Conducted multiple specialized trainings to the Sales, Medical Affairs, and Marketing teams
- Implemented a new software solution to streamline Sunshine Act compliance and tracking
- Conducted seven external speaker training sessions for healthcare professionals
- Monitored three industry conferences

Cybersecurity

With Board oversight and input, our IT team continues to strengthen our security posture while expanding its technical capabilities. In 2023, the Cybersecurity team conducted its annual risk assessment and developed risk treatment tasks, remediating all tasks in the first quarter.

Our cybersecurity posture is strengthened by a host of tools and processes including firewalls, endpoint protection, mail security, comprehensive identity and device management, real time vulnerability detection, robust backups, and a comprehensive disaster recovery system. In 2023, our efforts spoke for themselves with zero events:

- Zero network breaches
- Zero endpoints compromised
- Zero account takeovers
- Zero identities compromised
- Zero device takeovers
- Zero VPN intrusions

Data Privacy

We conduct our business and operations in compliance with the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”). In addition to HIPAA’s protection of individually identifiable health information, our Privacy Policy meets the standards of privacy protection accorded to both health data and other personal information established under the European Union General Data Protection Regulation (“GDPR”) and the California Consumer Privacy Act as amended.

Sustainability Accounting Standards Board (SASB) Index

All data as of 12/31/2023 unless otherwise noted.

Accounting Metric		SASB Code	Disclosure/Disclosure Location	Data
BIOTECHNOLOGY AND PHARMACEUTICALS STANDARDS				
Safety of Clinical Trial Participants	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	HC-BP-210a.1	p. 8 - 9	
	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	HC-BP-210a.2	p. 8 - 9	(1) 0 (2) 0
	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	HC-BP-210a.3	Any material legal or regulatory issues would be disclosed in AVITA Medical's annual 10-K (or sooner under ASX Listing Rules).	0
Affordability & Pricing	Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	HC-BP-240b.2	AVITA Medical considers this information proprietary and thus does not publicly report on it.	
	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period	HC-BP-240b.3	AVITA Medical considers this information proprietary and thus does not publicly report on it.	
Product Safety	Products listed in public medical product safety or adverse event alert databases	HC-BP-250a.1	p. 14	0
	Number of fatalities associated with products	HC-BP-250a.2	p. 14	0
	(1) Number of recalls issued, (2) total units recalled	HC-BP-250a.3	p. 14	(1) 0 (2) 0
	Total amount of product accepted for takeback, reuse, disposal, recycling, or donated	HC-BP-250a.4	p. 13	0.071 metric tons
	Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	HC-BP-250a.5	p. 14	0

Accounting Metric		SASB Code	Disclosure/Disclosure Location	Data
Counterfeit Devices	Description of efforts to maintain traceability within the distribution chain	HC-BP-260a.1	p. 13	
	Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	HC-BP-260a.2	p. 13	
	Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	HC-BP-260a.3	Any material legal or regulatory issues would be disclosed in AVITA Medical's annual 10-K (or sooner under ASX Listing Rules).	0
Ethical Marketing	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	HC-BP-270a.1	Any material legal or regulatory issues would be disclosed in AVITA Medical's annual 10-K (or sooner under ASX Listing Rules).	0
	Description of code of ethics governing promotion of off-label use of products	HC-BP-270a.2	p. 15	
Employee Recruitment, Development & Retention	Discussion of talent recruitment and retention efforts for scientists and research and development staff	HC-BP-330a.1	p. 11	
	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	HC-BP-330a.2	Due to the confidentiality of this metric and the competitive market for skilled labor in its industry, AVITA Medical does not report a turnover rate. Any significant departures from the company's executive or management team would be reflected in a Form 8-K filed with the SEC.	
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	HC-BP-510a.1	Any material legal or regulatory issues would be disclosed in AVITA Medical's annual 10-K (or sooner under ASX Listing Rules).	0
	Description of code of ethics governing interactions with health care professionals	HC-BP-510a.2	p. 15	

Accounting Metric		SASB Code	Disclosure/Disclosure Location	Data
Activity Metrics	Number of patients treated	HC-BP-000.A	p. 8	> 3,000
	Number of FDA Pre-Market Authorizations ("PMAs") or PMA Supplements (1) achieved and (2) in process in 2023	HC-BP-000.B	p. 8	(1) 5 (2) 1
MEDICAL EQUIPMENT AND SUPPLIES STANDARDS				
Product Design and Lifecycle Management	Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products	HC-MS-410a.1	p. 13	
Supply Chain Management	Percentage of (1) entity's facilities and (2) Tier 1 suppliers' facilities participating in third-party audit programs for manufacturing and product quality	HC-MS-430a.1	p. 14	(1) 100% (2) 100%
	Description of efforts to maintain traceability within the distribution chain	HC-MS-430a.2	p. 14	
	Description of the management of risks associated with the use of critical materials	HC-MS-430a.3	p. 14	
Activity Metrics	Number of units sold by product category	HC-MS-000.A	p. 8	7,110 RECELL devices were sold in 2023.

Sources

[1] Holmes JH, Molnar JA, Carter JE, et al. A comparative study of the RECELL® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. *J Burn Care Res.*2018 Aug 17;39(5):694-702.

[2] Holmes JH, Molnar JA, Shupp JW, et al. Demonstration of the safety and effectiveness of the RECELL® system combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. *Burns*.2019;45(4):772-782. *Care Res.* 2018;39(5):694-702.

[3] Henry S, Mapula S, Grevious M, et al. Maximizing wound coverage in full-thickness skin defects: A randomized controlled trial of autologous skin cell suspension and widely meshed autograft versus standard autografting. J Trauma Acute Care Surg. 2024;96(1):85-93. doi:10.1097/TA.0000000000004120.

[4] Kowal S, Kruger E, Bilir P, et al. Cost effectiveness of the use of autologous cell harvesting device compared to standard of care for treatment of severe burns in the United States. *Adv Ther.* Published online May 7, 2019. doi: 10.1007/s12325-019-00961-2.

[5] Foster K, Bilir P, Kruger E, et al. Cost-effectiveness of RECELL® Autologous Cell Harvesting Device (ACHD) versus STSG for treatment of severe burns in the United States. Presented at the American Burn Association 2018 Annual Meeting, April 2018.

[6] Carter JE, Carson JS, Hickerson WL, et al. Length of Stay and Costs with Autologous Skin Cell Suspension Versus Split-Thickness Skin Grafts: Burn Care Data from US Centers [published online ahead of print, 2022 Sep 14]. *Adv Ther*.2022;10.1007/s12325-022-02306-y. doi :10.1007/s12325-022-02306-y.